No-Reflow Phenomenon clinical trials
The registry lists 27 studies for No-Reflow Phenomenon across more than 10 countries. 9 are recruiting or about to start. 10 of them are mainly about No-Reflow Phenomenon (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-27.
Get an email when these change. Save the No-Reflow Phenomenon studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Assiut University (4) · Ain Shams University (3) · Fudan University (2) · National Institute of Cardiovascular Diseases, Pakistan (2) · Privolzhsky Research Medical University (1) · First Hospital of China Medical University (1) · Universität Duisburg-Essen (1) · Vascular and Molecular Cardiology Society (1)
What is being tested here
Drugs under test in No-Reflow Phenomenon studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Empagliflozin | 1 | 0 | 3 |
| Epinephrine | 1 | 1 | 3 |
| Nicorandil | 1 | 0 | 2 |
| Dapagliflozin | 1 | 0 | 1 |
| Rivaroxaban | 1 | 0 | 1 |
| Verapamil | 0 | 0 | 1 |
| Tirofiban | 0 | 0 | 1 |
| Diltiazem | 0 | 0 | 1 |
| Ticagrelor | 0 | 0 | 1 |
Drug classes tested here SGLT2 inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 3
- May 2027A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease · Korea University Anam Hospital
- Jun 2027Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI · Al-Azhar University
- Sep 2027Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular Thrombectomy · University of Zurich
Who these studies take
Of the 4 No-Reflow Phenomenon studies recruiting now, 3 (75%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 3 (75%) | 3 (75%) |
| 30 | 4 (100%) | 4 (100%) |
| 40 | 4 (100%) | 4 (100%) |
| 50 | 4 (100%) | 4 (100%) |
| 65 | 4 (100%) | 4 (100%) |
| 75 | 4 (100%) | 4 (100%) |
| 85 | 3 (75%) | 3 (75%) |
Across all 27 studies, recruiting or not: 7% stop at 75 or younger and 0% at 65; 15% take children; 0% are for women only and 0% for men only; 7% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 13, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 27 of 27. search them.
- Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCINot yet recruitingNCT07898709Phase 21 country
- A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery DiseaseRecruitingNCT05427786Phase 41 country
- Insulin Resistance and Its Association With no Reflow Phenomenon After Primary PCI in Type II Diabetic STEMI Patients.Not yet recruitingNCT07706335
- Adenosine Pre-Medication in Primary Percutaneous Coronary InterventionRecruitingNCT07536802Phase 41 country
- Investigation of Brain Blood Flow Changes in Acute Ischemic Stroke Patients After Successful Endovascular ThrombectomyRecruitingNCT075343191 country
- Rivaroxaban for Slow Coronary Flow After PCI in STEMINot yet recruitingNCT07195812Phase 4
- Validation of New Biomarkers for Predicting No-Reflow in STEMI Patients Undergoing Primary PCINot yet recruitingNCT07132489
- The Investigator Administers Intracoronary Adrenaline Via the Catheter in STEMI Patients During Primary PCI, After Flow Restoration and Before Stenting, and Studies Its Effect in Prevention of No ReflowRecruitingNCT06847568Phase 31 country
- Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial InfarctionNot yet recruitingNCT05393557Not applicable
- The EPIVER Randomized Controlled TrialCompletedNCT04573751Not applicable1 country
- Empagliflozin for No-reflow Phenomenon in PCI for STEMIActive, not recruitingNCT06342141Phase 21 country
- Genetic Determinants of the Coronary Microvascular Obstruction in PCICompletedNCT053555321 country
- Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCICompletedNCT07138508Phase 1/21 country
- Alpha Lipoic Acid Effect on No-Reflow PhenomenonCompletedNCT05360602Not applicable1 country
- Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.CompletedNCT047852091 country
- Adrenaline for the Treatment of No-Reflow in Normotensive PatientsCompletedNCT04699110Phase 41 country
- the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI)Status unknownNCT04835974Not applicable
- No Reflow Phenomenon Incidence and PredictorsCompletedNCT040171691 country
- Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial InfarctionCompletedNCT02131220Phase 41 country
- Empagliflozin on Cardiac-renal Injury in Patients With STEAMI Patients After Primary PCIStatus unknownNCT03591991Not applicable
- NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial InfarctionStatus unknownNCT032648591 country
- Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count MethodStatus unknownNCT02831153Not applicable1 country
- Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI)Status unknownNCT02818127Not applicable1 country
- Analysis of Human Coronary AspirateStatus unknownNCT014308841 country
- Ticagrelor and Clopidogrel on Reperfusion in Patients With AMIStatus unknownNCT02233790Phase 41 country
- Intracoronary Tirofiban on No-Reflow PhenomenaCompletedNCT02054000Phase 41 country
- Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial InfarctionCompletedNCT00712894Phase 41 country